AtriCure, Inc. (ATRC)

Market Cap	1.50B
Revenue (ttm)	447.57M
Net Income (ttm)	-38.92M
Shares Out	48.75M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600,938
Open	29.83
Previous Close	30.05
Day's Range	29.56 - 31.02
52-Week Range	18.94 - 39.05
Beta	1.40
Analysts	Strong Buy
Price Target	41.78 (+36.0%)
Earnings Date	Feb 13, 2025

About ATRC

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensin...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 5, 2005
• Employees: 1,200
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRC
• Website: https://www.atricure.com

Financial Performance

In 2023, AtriCure's revenue was $399.25 million, an increase of 20.84% compared to the previous year's $330.38 million. Losses were -$30.44 million, -34.49% less than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for ATRC stock is "Strong Buy." The 12-month stock price forecast is $41.78, which is an increase of 36.00% from the latest price.

Price Target

$41.78

(36.00% upside)

Analyst Consensus: Strong Buy